sábado, 3 de agosto de 2019

CMS NEWS: Trump Administration Finalizes Policies to Advance Rural Health and Medical Innovation

Centers for Medicare & Medicaid Services
CMS.gov News Room

CMS NEWS

FOR IMMEDIATE RELEASE
August 2, 2019
Contact: CMS Media Relations
(202) 690-6145 | CMS Media Inquiries

Trump Administration Finalizes Policies to Advance Rural Health and Medical InnovationHistoric changes to the Inpatient Prospective Payment System (IPPS) and Long-Term Care Hospital (LTCH) Prospective Payment System mean better quality and access
Today, under the leadership of President Trump, the Centers for Medicare & Medicaid Services (CMS) finalized policy changes to spur competition and innovation that will help deliver improved care and outcomes at a better value to patients. The final rule updates Medicare payment policies for hospitals under the Inpatient Prospective Payment System (IPPS) and the Long-Term Care Hospital (LTCH) Prospective Payment System (PPS) for fiscal year 2020 and advances two key CMS priorities—“Rethinking Rural Health” and “Unleashing Innovation”—by making historic changes to how Medicare pays hospitals.
“The Trump Administration is providing relief to rural communities and addressing payment policies that have disadvantaged rural hospitals, making it harder for them to stay open and provide care to the one in five Americans living in rural areas,” said CMS Administrator Seema Verma. “The changes we’re finalizing in today’s rule are long overdue and improve the way Medicare pays hospitals, which will help many rural hospitals maintain their healthcare labor force, to ensure that patients have access to high-quality, affordable healthcare.”
In last year’s proposed rule, CMS invited comments on changes to the Medicare inpatient hospital wage index, which is an adjustment to inpatient payment rates to account for local differences in wages that hospitals face in their respective labor markets. A common concern from the public was that the current wage index system worsens wage index disparities between hospitals in high-wage areas and low-wage areas, which tend to be rural.  Rural areas have experienced more than 100 hospital closures since 2010 and continue to face limited access to specialty care.
This final rule addresses these disparities by increasing the wage index for certain low-wage index hospitals, including many rural hospitals, and ensures rural Americans have access to needed care. The wage index is intended to measure differences in hospital wage levels across geographic regions and is updated annually based on wage data reported by hospitals. Hospitals located in areas with wages below the national average receive a lower Medicare payment rate than hospitals in areas with above-average wages. For example, a hospital in a low-wage rural community could receive a Medicare payment of about $4,000 for treating a beneficiary admitted for pneumonia, while a hospital in a high-wage area (many urban communities) could receive a Medicare payment of nearly $6,000 for the same case due to wage index differences. With the changes made to the hospital wage index, CMS is helping many rural and other low-wage hospitals attract and maintain a highly skilled workforce, which will strengthen competition and lead to greater choice for patients in rural areas.
This final rule also ensures Medicare beneficiaries will have access to a world-class healthcare system by unleashing medical innovation, removing barriers to competition, and enabling faster access to new medical technology through several payment changes.
“President Trump is strengthening Medicare by clearing the way for Medicare beneficiaries to access the same transformative technologies and treatment options emerging in the private market,” said Administrator Verma. “Through our efforts to improve transparency and reduce regulatory burden, we are hearing more than ever from innovators who want to work with us so that Medicare beneficiaries have access to the latest advances in healthcare.”
This final rule increases Medicare add-on payments known as the new technology add-on payment (NTAP) for cases with high costs involving eligible new technologies. The increased payment from 50% to 65% will promote patient access and reduce uncertainty that innovators face about Medicare payment for new medical technologies.
CMS is also modernizing payment policies for medical devices that meet the FDA’s Breakthrough Devices designation for expedited FDA approval or clearance. Under an expedited timeframe, it can be challenging for innovators to gather evidence of the device’s “substantial clinical improvement” which is required to qualify for Medicare new technology add-on payments. To address this issue, CMS finalized an alternative NTAP pathway in which Breakthrough Devices would no longer be required to demonstrate evidence of  “substantial clinical improvement” to qualify for new technology add-on payments. This will provide additional Medicare payment for these technologies while real-world evidence is emerging, giving Medicare beneficiaries timely access to the latest innovations in treatment. And, to give innovators greater transparency and predictability on the CMS NTAP approval process, CMS is finalizing changes to clarify our general policies on “substantial clinical improvement” to qualify for new technology add on payments.
CMS is also finalizing policies to remove barriers for new antimicrobial therapies, which treat drug-resistant infections, and are currently in short supply. Drug-resistant infections are a public health crisis, affecting more than 2 million Americans each year and resulting in thousands of deaths annually, with the majority of new diagnoses and subsequent fatalities attributed to Medicare beneficiaries. To encourage the development of antimicrobials, CMS has also created an alternative NTAP pathway, which would no longer require new antimicrobial drugs to meet the “substantial clinical improvement” criteria and would also increase the NTAP from 50% to 75%. Importantly, the drugs eligible for this pathway will be new antimicrobials which have received a Qualified Infectious Disease Products (QIDP) designation from the FDA. These particular antibiotics are specifically designed with the intent of addressing resistant infections.
Modernizing the evidence requirement and payment level in a targeted manner will help foster innovation and improve outcomes for patients.  
The IPPS and LTCH PPS final rule is one of five Medicare payment rules released on a fiscal year cycle to define payment and policy for inpatient hospitals, long term care hospitals, inpatient rehabilitation facilities, inpatient psychiatric facilities, skilled nursing facilities, and hospices.
To view the final rule (CMS-1716-F), please visit: https://www.federalregister.gov/public-inspection

No hay comentarios: